Literature DB >> 34397951

Dose-dependent association between blood transfusion and nosocomial infections in trauma patients: A secondary analysis of patients from the PAMPer trial.

Husayn A Ladhani1, Vanessa P Ho, C Clare Charbonnet, Jason L Sperry, Francis X Guyette, Joshua B Brown, Brian J Daley, Richard S Miller, Brian G Harbrecht, Herb A Phelan, Jeffrey A Claridge.   

Abstract

BACKGROUND: The Prehospital Air Medical Plasma (PAMPer) trial demonstrated a survival benefit to trauma patients who received thawed plasma as part of early resuscitation. The objective of our study was to examine the association between blood transfusion and nosocomial infections among trauma patients who participated in the PAMPer trial. We hypothesized that transfusion of blood products will be associated with the development of nosocomial infections in a dose-dependent fashion.
METHODS: We performed a secondary analysis of prospectively collected data of patients in the PAMPer trial with hospital length of stay of at least 3 days. Demographics, injury characteristics, and number of blood products transfused were obtained to evaluate outcomes. Bivariate analysis was performed to identify differences between patients with and without nosocomial infections. Two logistic regression models were created to evaluate the association between nosocomial infections and (1) any transfusion of blood products, and (2) quantity of blood products. Both models were adjusted for age, sex, and Injury Severity Score.
RESULTS: A total of 399 patients were included: age, 46 years (interquartile range, 29-59 years); Injury Severity Score, 22 (interquartile range, 12-29); 73% male; 80% blunt mechanism; and 40 (10%) deaths. Ninety-three (27%) developed nosocomial infections, including pneumonia (n = 67), bloodstream infections (n = 14), catheter-associated urinary tract infection (n = 10), skin and soft tissue infection (n = 8), Clostridium difficile colitis (n = 7), empyema (n = 6), and complicated intra-abdominal infections (n = 3). Nearly 80% (n = 307) of patients received packed red blood cells (PRBCs); 12% received cryoprecipitate, 69% received plasma, and 27% received platelets. Patients who received any PRBCs had more than a twofold increase in nosocomial infections (odds ratio, 2.15; 95% confidence interval, 1.01-4.58; p = 0.047). The number of PRBCs given was also associated with the development of nosocomial infection (odds ratio, 1.10; 95% confidence interval, 1.05-1.16; p < 0.001).
CONCLUSION: Trauma patients in the PAMPer trial who received a transfusion of at least 1 U of PRBCs incurred a twofold increased risk of nosocomial infection, and the risk of infection was dose dependent. LEVEL OF EVIDENCE: Therapeutic/care management, level IV.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34397951      PMCID: PMC8664092          DOI: 10.1097/TA.0000000000003251

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.697


  21 in total

1.  Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial.

Authors:  John B Holcomb; Barbara C Tilley; Sarah Baraniuk; Erin E Fox; Charles E Wade; Jeanette M Podbielski; Deborah J del Junco; Karen J Brasel; Eileen M Bulger; Rachael A Callcut; Mitchell Jay Cohen; Bryan A Cotton; Timothy C Fabian; Kenji Inaba; Jeffrey D Kerby; Peter Muskat; Terence O'Keeffe; Sandro Rizoli; Bryce R H Robinson; Thomas M Scalea; Martin A Schreiber; Deborah M Stein; Jordan A Weinberg; Jeannie L Callum; John R Hess; Nena Matijevic; Christopher N Miller; Jean-Francois Pittet; David B Hoyt; Gail D Pearson; Brian Leroux; Gerald van Belle
Journal:  JAMA       Date:  2015-02-03       Impact factor: 56.272

Review 2.  Blood transfusion-induced immunomodulation.

Authors:  D F Landers; G E Hill; K C Wong; I J Fox
Journal:  Anesth Analg       Date:  1996-01       Impact factor: 5.108

3.  The dose-dependent relationship between blood transfusions and infections after trauma: A population-based study.

Authors:  Charlie J Nederpelt; Majed El Hechi; Jonathan Parks; Jason Fawley; April E Mendoza; Noelle Saillant; David R King; Peter J Fagenholz; George C Velmahos; Haytham M A Kaafarani
Journal:  J Trauma Acute Care Surg       Date:  2020-07       Impact factor: 3.313

4.  Pretrauma center red blood cell transfusion is associated with reduced mortality and coagulopathy in severely injured patients with blunt trauma.

Authors:  Joshua B Brown; Mitchell J Cohen; Joseph P Minei; Ronald V Maier; Michaela A West; Timothy R Billiar; Andrew B Peitzman; Ernest E Moore; Joseph Cuschieri; Jason L Sperry
Journal:  Ann Surg       Date:  2015-05       Impact factor: 12.969

5.  Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial.

Authors:  L M van de Watering; J Hermans; J G Houbiers; P J van den Broek; H Bouter; F Boer; M S Harvey; H A Huysmans; A Brand
Journal:  Circulation       Date:  1998-02-17       Impact factor: 29.690

6.  Plasma-first resuscitation to treat haemorrhagic shock during emergency ground transportation in an urban area: a randomised trial.

Authors:  Hunter B Moore; Ernest E Moore; Michael P Chapman; Kevin McVaney; Gary Bryskiewicz; Robert Blechar; Theresa Chin; Clay Cothren Burlew; Fredric Pieracci; F Bernadette West; Courtney D Fleming; Arsen Ghasabyan; James Chandler; Christopher C Silliman; Anirban Banerjee; Angela Sauaia
Journal:  Lancet       Date:  2018-07-20       Impact factor: 79.321

7.  Allogenic blood transfusion in the first 24 hours after trauma is associated with increased systemic inflammatory response syndrome (SIRS) and death.

Authors:  James R Dunne; Debra L Malone; J Kathleen Tracy; Lena M Napolitano
Journal:  Surg Infect (Larchmt)       Date:  2004       Impact factor: 2.150

8.  The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks.

Authors:  John B Holcomb; Deborah J del Junco; Erin E Fox; Charles E Wade; Mitchell J Cohen; Martin A Schreiber; Louis H Alarcon; Yu Bai; Karen J Brasel; Eileen M Bulger; Bryan A Cotton; Nena Matijevic; Peter Muskat; John G Myers; Herb A Phelan; Christopher E White; Jiajie Zhang; Mohammad H Rahbar
Journal:  JAMA Surg       Date:  2013-02       Impact factor: 14.766

9.  Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic Shock.

Authors:  Jason L Sperry; Francis X Guyette; Joshua B Brown; Mark H Yazer; Darrell J Triulzi; Barbara J Early-Young; Peter W Adams; Brian J Daley; Richard S Miller; Brian G Harbrecht; Jeffrey A Claridge; Herb A Phelan; William R Witham; A Tyler Putnam; Therese M Duane; Louis H Alarcon; Clifton W Callaway; Brian S Zuckerbraun; Matthew D Neal; Matthew R Rosengart; Raquel M Forsythe; Timothy R Billiar; Donald M Yealy; Andrew B Peitzman; Mazen S Zenati
Journal:  N Engl J Med       Date:  2018-07-26       Impact factor: 91.245

10.  Prehospital Blood Product and Crystalloid Resuscitation in the Severely Injured Patient: A Secondary Analysis of the Prehospital Air Medical Plasma Trial.

Authors:  Francis X Guyette; Jason L Sperry; Andrew B Peitzman; Timothy R Billiar; Brian J Daley; Richard S Miller; Brian G Harbrecht; Jeffrey A Claridge; Tyler Putnam; Therese M Duane; Herb A Phelan; Joshua B Brown
Journal:  Ann Surg       Date:  2021-02-01       Impact factor: 13.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.